Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Superselective Drug-Eluting Chemoembolization With HepaSphere in Unresectable Advanced HCC Patients: Safety & Efficacy Registry in China (SUPER-China)

NCT02743065 is registered in ClinicalTrials.gov with Fifth Affiliated Hospital, Sun Yat-Sen University as lead sponsor.

NCT NCT02743065
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02743065 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Superselective Drug-Eluting Chemoembolization With HepaSphere in Unresectable Advanced HCC Patients: Safety & Efficacy Registry in China (SUPER-China)
Lead sponsor
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase
Observational
Overall status
Unknown status
Start date
September 30, 2016
Completion date
December 31, 2019
Enrollment
100 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma